ALDMS Fundamental Analysis - DIAGNOSTIC MEDICAL SYSTEMS

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to ALDMS. ALDMS was compared to 63 industry peers in the Health Care Equipment & Supplies industry. ALDMS may be in some trouble as it scores bad on both profitability and health. ALDMS is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

ALDMS had negative earnings in the past year.

In the past year ALDMS had a positive cash flow from operations.

In the past 5 years ALDMS always reported negative net income.

The reported operating cash flow has been mixed in the past 5 years: ALDMS reported negative operating cash flow in multiple years.

1.2 Ratios

The Return On Assets of ALDMS (-5.34%) is worse than 71.21% of its industry peers.

ALDMS has a worse Return On Equity (-22.44%) than 74.24% of its industry peers.

		Industry Rank	Sector Rank
ROA	-5.34%
ROE	-22.44%
ROIC	N/A

ROA(3y)-9.22%

ROA(5y)-9.28%

ROE(3y)-35.31%

ROE(5y)-31.48%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ALDMS has a worse Gross Margin (39.92%) than 77.27% of its industry peers.

In the last couple of years the Gross Margin of ALDMS has grown nicely.

The Profit Margin and Operating Margin are not available for ALDMS so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	39.92%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y2.05%

GM growth 5Y2.79%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALDMS does not have a ROIC to compare to the WACC, probably because it is not profitable.

ALDMS has more shares outstanding than it did 1 year ago.

ALDMS has more shares outstanding than it did 5 years ago.

The debt/assets ratio for ALDMS has been reduced compared to a year ago.

2.2 Solvency

ALDMS has an Altman-Z score of 1.03. This is a bad value and indicates that ALDMS is not financially healthy and even has some risk of bankruptcy.

ALDMS has a Altman-Z score of 1.03. This is in the lower half of the industry: ALDMS underperforms 71.21% of its industry peers.

The Debt to FCF ratio of ALDMS is 5.57, which is a neutral value as it means it would take ALDMS, 5.57 years of fcf income to pay off all of its debts.

The Debt to FCF ratio of ALDMS (5.57) is comparable to the rest of the industry.

A Debt/Equity ratio of 0.90 indicates that ALDMS is somewhat dependend on debt financing.

Looking at the Debt to Equity ratio, with a value of 0.90, ALDMS is doing worse than 78.79% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.9
Debt/FCF	5.57
Altman-Z	1.03

ROIC/WACCN/A

WACC7.11%

2.3 Liquidity

ALDMS has a Current Ratio of 1.29. This is a normal value and indicates that ALDMS is financially healthy and should not expect problems in meeting its short term obligations.

ALDMS's Current ratio of 1.29 is on the low side compared to the rest of the industry. ALDMS is outperformed by 60.61% of its industry peers.

A Quick Ratio of 0.67 indicates that ALDMS may have some problems paying its short term obligations.

ALDMS's Quick ratio of 0.67 is on the low side compared to the rest of the industry. ALDMS is outperformed by 77.27% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.29
Quick Ratio	0.67

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 40.00% over the past year.

The Revenue has grown by 9.29% in the past year. This is quite good.

The Revenue has been growing by 8.24% on average over the past years. This is quite good.

EPS 1Y (TTM)40%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%87%

Revenue 1Y (TTM)9.29%

Revenue growth 3Y7.62%

Revenue growth 5Y8.24%

Sales Q2Q%8.7%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

ALDMS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.02% yearly.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year13.75%

Revenue Next 2Y13.01%

Revenue Next 3Y12.65%

Revenue Next 5Y13.02%

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALDMS. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, ALDMS is valued cheaper than 93.94% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	9.29
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ALDMS!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

DIAGNOSTIC MEDICAL SYSTEMS

EPA:ALDMS (12/5/2025, 7:00:00 PM)

1.255

-0.03 (-1.95%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst Owners6.3%

Inst Owner ChangeN/A

Ins Owners3.37%

Ins Owner ChangeN/A

Market Cap33.45M

Revenue(TTM)46.07M

Net Income(TTM)-2.88M

Analysts86

Price Target2.2 (75.3%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)5.37%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)-1.57%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.73
P/FCF	9.29
P/OCF	9.29
P/B	2.61
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-0.15

EYN/A

EPS(NY)0

Fwd EYN/A

FCF(TTM)0.14

FCFY10.77%

OCF(TTM)0.14

OCFY10.77%

SpS1.73

BVpS0.48

TBVpS-0.22

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-5.34%
ROE	-22.44%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	39.92%
FCFM	7.82%

ROA(3y)-9.22%

ROA(5y)-9.28%

ROE(3y)-35.31%

ROE(5y)-31.48%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y2.05%

GM growth 5Y2.79%

F-Score6

Asset Turnover0.85

Health

		Industry Rank	Sector Rank
Debt/Equity	0.9
Debt/FCF	5.57
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.29
Quick Ratio	0.67
Altman-Z	1.03

F-Score6

WACC7.11%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)40%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%87%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)9.29%

Revenue growth 3Y7.62%

Revenue growth 5Y8.24%

Sales Q2Q%8.7%

Revenue Next Year13.75%

Revenue Next 2Y13.01%

Revenue Next 3Y12.65%

Revenue Next 5Y13.02%

EBIT growth 1Y35.01%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year1000%

EBIT Next 3Y174.79%

EBIT Next 5Y101.77%

FCF growth 1Y318.91%

FCF growth 3YN/A

FCF growth 5Y58.15%

OCF growth 1Y318.91%

OCF growth 3YN/A

OCF growth 5Y58.15%

DIAGNOSTIC MEDICAL SYSTEMS / ALDMS.PA FAQ

What is the fundamental rating for ALDMS stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALDMS.PA.

What is the valuation status for ALDMS stock?

ChartMill assigns a valuation rating of 2 / 10 to DIAGNOSTIC MEDICAL SYSTEMS (ALDMS.PA). This can be considered as Overvalued.

How profitable is DIAGNOSTIC MEDICAL SYSTEMS (ALDMS.PA) stock?

DIAGNOSTIC MEDICAL SYSTEMS (ALDMS.PA) has a profitability rating of 1 / 10.

DIAGNOSTIC MEDICAL SYSTEMS (ALDMS.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

DIAGNOSTIC MEDICAL SYSTEMS / ALDMS.PA FAQ

What is the fundamental rating for ALDMS stock?

What is the valuation status for ALDMS stock?

How profitable is DIAGNOSTIC MEDICAL SYSTEMS (ALDMS.PA) stock?